IRF5 is elevated in childhood-onset SLE and regulated by histone acetyltransferase and histone deacetylase inhibitors.

about

IRF5 is elevated in childhood-onset SLE and regulated by histone acetyltransferase and histone deacetylase inhibitors.

Item

http://www.wikidata.org/entity/Q41470976

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

IRF5 is elevated in childhood- ...... istone deacetylase inhibitors.

@en

type

Item

label

IRF5 is elevated in childhood- ...... istone deacetylase inhibitors.

@en

prefLabel

IRF5 is elevated in childhood- ...... istone deacetylase inhibitors.

@en

P1476

IRF5 is elevated in childhood- ...... istone deacetylase inhibitors.

@en

P2093

Guo-Ping Zhou

http://www.w3.org/2001/XMLSchema#string

Hai-Guo Yu

http://www.w3.org/2001/XMLSchema#string

Jin Shu

http://www.w3.org/2001/XMLSchema#string

Jun Qian

http://www.w3.org/2001/XMLSchema#string

Lan-Bo Zhou

http://www.w3.org/2001/XMLSchema#string

Li-Li Zhuang

http://www.w3.org/2001/XMLSchema#string

Ling Li

http://www.w3.org/2001/XMLSchema#string

Lu-Lu Wang

http://www.w3.org/2001/XMLSchema#string

Rui Jin

http://www.w3.org/2001/XMLSchema#string

Zhi-Dan Fan

http://www.w3.org/2001/XMLSchema#string

P2860

IRF5 is required for late-phase TNF secretion by human dendritic cells

Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus

A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus

Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

HDAC inhibition decreases the expression of EGFR in colorectal cancer cells.

Contribution of IRF5 in B cells to the development of murine SLE-like disease through its transcriptional control of the IgG2a locus.

The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo

Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse.

Histone deacetylase 9 deficiency protects against effector T cell-mediated systemic autoimmunity

P304

47184-47194

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.17586

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-05-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28525378

http://www.w3.org/2001/XMLSchema#string

P932

5564555

http://www.w3.org/2001/XMLSchema#string